These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26472335)

  • 1. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth.
    Stone KA
    Harm Reduct J; 2015 Oct; 12():32. PubMed ID: 26472335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
    Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Global State of Harm Reduction in Prisons.
    Sander G; Shirley-Beavan S; Stone K
    J Correct Health Care; 2019 Apr; 25(2):105-120. PubMed ID: 31084277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
    Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P
    Lancet; 2016 Sep; 388(10050):1228-48. PubMed ID: 27427455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
    MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
    Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The furthest left behind: the urgent need to scale up harm reduction in prisons.
    Sander G; Murphy F
    Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.
    Fernandes RM; Cary M; Duarte G; Jesus G; Alarcão J; Torre C; Costa S; Costa J; Carneiro AV
    BMC Public Health; 2017 Apr; 17(1):309. PubMed ID: 28399843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases.
    Stöver H; Tarján A; Horváth G; Montanari L
    Harm Reduct J; 2021 Jun; 18(1):67. PubMed ID: 34187471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
    Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
    J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-related HIV epidemic in Pakistan: a review of current situation and response and the way forward beyond 2015.
    Bergenstrom A; Achakzai B; Furqan S; ul Haq M; Khan R; Saba M
    Harm Reduct J; 2015 Oct; 12():43. PubMed ID: 26471874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
    Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
    Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review.
    Abdul-Quader AS; Feelemyer J; Modi S; Stein ES; Briceno A; Semaan S; Horvath T; Kennedy GE; Des Jarlais DC
    AIDS Behav; 2013 Nov; 17(9):2878-92. PubMed ID: 23975473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
    van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
    Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
    Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
    Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.